EBMT-EHA CAR-T 2019 | The future of treating pediatric patients with hematological malignancies
Claudia Rössig, MD, of the University of Münster, Münster, Germany discusses the future for CAR T-cell therapy in pediatrics. In pediatrics, CAR T-cel therapy has reached a high cure rate in the acute lymphoblastic leukemia (ALL) indication. However, Dr Rössig explains that there is now a challenge to improve this further and reduce toxicities. There is a hope for CAR T-cell therapy to act as a standalone therapy for children with ALL, replacing toxic components of chemotherapy and stem cell transplantation, and have better long term outcomes. Recorded at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA).
Get great new content delivered to your inboxSign up